Miriam, 35, is looking for a treatment made from her own tumor.
She's a software engineer. Her tumor doesn't fit the usual protocols, and she has set out to investigate it in the open, with doctors and labs in several countries.
Clinician or lab? See what we need€98,482 raised on GoFundMe · 2,355 donors
First check-up blood test on the ADCMade with Polaris
Case tools
Miriam is an engineer. With Polaris, the AI system she built for her case, she turns reports, scans and samples into tools anyone can open.
The case in 3 sentences
- Miriam has metastatic breast cancer.
- A diagnosis that fit no protocol.
- The standard treatment isn't enough: it has to be designed around her specific tumor.
In her own words
My tumor has two sides, the breast side and the neuroendocrine one, and the key is to treat both at once, not just one.
— Miriam González. May 2026.
Where we are and what's left
Now: Datopotamab deruxtecan · since Oct 7, 2026
The aim is to reach no evidence of disease: the tests stop finding the cancer, and it stays that way. This is the route, step by step. Treatment to keep the disease in check carries on alongside it.
1 of 5 steps taken · 1 in progress
The bar counts the steps of this route already taken. It does not measure progress toward any medical goal.
- Keep the tumourDone
- Read the tumourIn progress
- Find the targetsPending
- Design the therapyPending
- Reach itOpen
What we’re looking for
- Trials or access programs (any country) for after TROPION-Breast06 that accept: no prior chemotherapy, HR+/HER2 IHC 0, a neuroendocrine component, liver metastases, Hb around 9-10 g/dL and a prior anti-TROP2 (the Dato-DXd of TROPION-Breast06). With checked figures: TB06 does not close NEXTGEN-TIL (NCT05141474) or TROPIKANA (NCT06066424); it does close other topoisomerase I ADCs
- Laboratories or groups able to predict and validate neoantigens from paraffin (tumor/germline WES + 10x Flex scRNA-seq with first results) and to manufacture personalized therapy (neoantigen vaccine, TIL, TCR-T, CAR-T) for an HR+/HER2 0 breast carcinoma with neuroendocrine differentiation and liver metastases inferredThe first results are in Cell by cell
- Radiology: expert read of the liver (correspondence of the 3 PET foci without a CT lesion; s.II target growing with low SUV; advisability of liver MRI with hepatocyte-specific contrast or multiphase CT to characterize the lesions <10 mm)
Where the money goes
What the money is for
The money received goes to the costs of the case; the expense report lists the line items, gift tax included, with its date.
See the expense reportCampaign phases
Molecular rebiopsy · done
Zürich, 8 July 2026. The tissue is still being analyzed.
Tissue bank · in progress
Preserve and bank the tissue and complete sequencing.
Personalized therapy · budget in progress
Start the combined approach: breast and neuroendocrine.
Join the people already making it possible.
Support Miriam (opens in a new tab)Official campaign
My official fundraiser is this one:
gofundme.com/f/biopsia-molecular-que-puede-cambiar-su-tratamiento (opens in a new tab)If you see any other campaign, fundraiser or initiative in my name, I didn't create it and I don't manage it.
How to help
Going through something similar? You don't have to contribute anything.Write to Miriam